How much funding has Recludix Pharma raised?

Recludix Pharma has raised $81.5M in total funding, most recently a Series B round.

Who are Recludix Pharma's investors?

Recludix Pharma's investors include NEA, Eli Lilly, Alexandria Venture Investments, Westlake Village BioPartners, Access Industries.

When was Recludix Pharma founded?

Recludix Pharma was founded in 2019.

Where is Recludix Pharma headquartered?

Recludix Pharma is headquartered in San Diego.

What industry is Recludix Pharma in?

Recludix Pharma operates in Biotech, Oncology.

How many employees does Recludix Pharma have?

Recludix Pharma has 11-50 employees.

Recludix Pharma

Unlocking new therapeutic possibilities

San Diego · Founded 2019 · $81.5M raised

Biotech

Oncology

Headquarters: San Diego
Employees: 11–50
Founded: 2019
Business Model: B2B

Website: recludixpharma.com
Total Funding: $81.5M
Last Round: $21.5M Series BJan 2026
Rounds: 2

About

Recludix Pharma is a clinical-stage biopharmaceutical company developing platform-based approaches to discover potent and selective inhibitors of challenging protein targets, with a focus on SH2 domain-containing proteins. The company's proprietary platform integrates structural biology, computational chemistry, and medicinal chemistry to tackle previously elusive but biologically validated targets. Recludix's lead programs target STAT6 and BTK for inflammatory diseases and oncology indications. The company was recognized as a Fierce 15 Biotech Company in 2024.

Summary

Recludix Pharma is a Biotech company based in San Diego, founded in 2019. It has raised $81.5M in total across 2 rounds, most recently a $21.5M Series B round in Jan 2026. Investors include NEA, Eli Lilly and Alexandria Venture Investments.